About: Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 06 September 2006

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2006 (uk) im September 2006 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 06 September 2006 (en) artículu científicu espublizáu en setiembre de 2006 (ast)
publication date	wds:Q80222693-B36B3DCD-D15E-48DD-A36D-C4053E4C7109
publication date	2006-09-06 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q80222693-1C107B7A-B443-410E-BCBE-AF11BB37189B
language of work or name	English
author name string	wds:Q80222693-7F1299DE-E7EA-4222-A760-90E66B4F2684 wds:Q80222693-96257B2C-EA98-490F-8343-0DF26CFCD6FF wds:Q80222693-96308E0E-F179-48FC-8F16-604BFE63F8C0 wds:Q80222693-9F55BA99-4FEB-4A8C-82B9-CD025DC742FF wds:Q80222693-F5D91C49-339C-430C-80B9-146579E7854B wds:Q80222693-F7FF9BF7-2D77-43A3-B171-9E83A23C918A
author name string	Rosa Ruiz-Valderas Josefa Ruiz-Morales Fernando Lozano Antonio Vergara de Campos Eva Leon Rebeca Valiente
rdfs:label	Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen (en) Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen (nl)
skos:prefLabel	Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen (en) Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen (nl)
name	Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen (en) Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen (nl)
author	wds:Q80222693-15ED766E-C657-4744-A0A5-44D3BABE6623 wds:Q80222693-75E9D6B8-84EE-4AFE-95B8-90CD068A13F9 wds:Q80222693-AE2C426C-D7E7-471B-97E4-553829C4158C
author	Luis Fernando López-Cortés Manuel Márquez Solero Ana Marín Niebla
title	wds:Q80222693-15265CE4-A481-4BD2-B1F6-A285F11CAB8A
title	Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen (en)
page(s)	wds:Q80222693-92FE2C76-B35C-4705-B5AD-E94E16A9489F
page(s)	1017-1023
instance of	wds:Q80222693-4D92ACA5-6F11-41E8-9FBE-28C470A04D42
instance of	scholarly article
main subject	wds:Q80222693-3BBA7FAC-8B0F-46F9-8318-66B858347A4F
main subject	wd:Q422645
PubMed ID	wds:Q80222693-8C36BD48-C11C-49F2-AD9F-8212F7D2BF99
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16956905
PubMed ID	16956905
published in	wds:Q80222693-6B09A494-0F3E-4973-9581-F5B3F64B7FC6
published in	Journal of Antimicrobial Chemotherapy
issue	wds:Q80222693-DFF04924-6AD7-4BBD-80CE-E26516295501
volume	wds:Q80222693-40EEB9B2-44A7-4D02-9B8F-4C2BFA3C4C7E
issue	5
volume	58
DOI	wds:Q80222693-02B2F170-D4AD-4740-B7F8-4A4E54DE7A4F
DOI	http://dx.doi.org/10.1093/JAC/DKL357
DOI	10.1093/JAC/DKL357
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q80222693
is cites work of	CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis CYP2B6 (c.516G→T) and CYP2A6 (9B and/or 17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin Decreased plasma efavirenz concentrations in a patient receiving rifabutin
is cites work of	wds:Q37466856-07D606D8-0F19-46AD-931D-B1D45B250BB3 wds:Q90018569-5F54F743-2A1A-4CCC-9CB1-BD0ED0AB4FDC wds:Q45575667-9A636213-94C1-49D9-BD0F-24426422A6E1 wds:Q24609011-3A14FBE5-E522-477D-879C-D987EFB7CD78 wds:Q37184431-790F045B-1721-46F1-A787-C5C690813B27 wds:Q35065867-36C848D5-AD48-45D8-9483-60AB8EC39123 wds:Q37115738-1E25819F-BF3E-485A-91FD-541B174102FE

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software